Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify

Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify

Source: 
BioPharma Dive
snippet: 

Vertex will pay privately held biotech Skyhawk Therapeutics $40 million up front in a deal to develop small molecule drugs that can modify RNA and treat unspecified "serious diseases."